Sanjivani Pa Peer Comparison

BSE: 531569

₹190.45

₹-3.90 (-2.01%)

As on 03-Sep-2026IST

Market cap

₹233 Cr

Revenue (TTM)

₹75 Cr

P/E Ratio

31.3

P/B Ratio

4.6

Div. Yield

0 %

Edit

	Sanjivani Pa	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Market cap (₹ Cr)	233	21,256	21,609	18,008	17,367
Revenue (₹ Cr)	75	2,570	2,287	3,230	2,432
Net Profit (₹ Cr)	7.45	735.15	678.07	666.92	169.62
Net Margin (%)	9.83	26.88	28.10	20.60	6.90
RoE (%)	16.04	19.16	19.73	18.75	20.76
Price to Earnings	31.25	28.91	32.48	27.97	102.39
Price-To-Book	4.60	4.82	5.74	4.45	19.21

Income Statement (₹ Cr)

	Sanjivani Pa	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Operating Revenue	66.33	2,569.77	2,287.33	3,229.67	2,432.06
Total Income	67.68	2,735.39	2,413.29	3,237.12	2,458.54
Total Expenditure	56.18	1,628.14	1,490.75	2,090.06	2,202.20
EBITDA	10.15	941.63	796.58	1,139.61	229.86
Depreciation	1.01	57.58	78.10	281.06	17.24
EBIT	9.14	884.05	718.48	858.55	212.62
Interest	0.50	7.69	0.88	190.64	5.72
Other Income	1.35	165.62	125.96	7.45	26.48
Exceptional Items	0.00	-49.16	0.00	-17.24	-5.13
Profit before Tax	9.99	992.82	843.56	658.12	228.25
Provision for Tax	2.50	257.67	165.49	-8.80	58.63
Profit after Tax	7.49	735.15	678.07	666.92	169.62

	Sanjivani Pa	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Shareholder's Funds	48.39	4,202.90	3,586.42	3,902.67	872.79
Minority Interest	0.00	0.00	-12.71	-21.81	0.00
Non-Current Liabilities	8.46	91.50	28.74	1,392.75	134.50
Current Liabilities	21.58	627.48	385.94	2,077.10	981.81
Total Liabilities	--	4,911.11	3,207.85	6,865.52	1,879.19

	Sanjivani Pa	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Non-Current Assets	29.05	770.28	1,291.22	5,617.77	42.47
Current Assets	48.28	3,803.22	2,585.66	1,539.85	1,739.93
Total Assets	--	4,911.11	3,207.85	6,865.52	1,879.19
Total Debt*	--	2.50	0.55	2,421.66	0.00
Net Current Assets	26.71	3,175.74	2,199.72	-537.25	758.12
Contingent Liabilities	--	363.79	0.64	51.96	98.41

	Sanjivani Pa	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Cash From Operating Activities	--	659.75	432.37	1,065.01	65.36
Cash Flow from Investing Activities	--	-71.34	-334.73	-79.97	30.80
Cash from Financing Activities	--	-205.34	-38.32	-881.32	-65.59
Net Cash Inflow / Outflow	--	383.07	59.32	103.72	30.57

	Sanjivani Pa	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
ROCE (%)	--	26.21	26.22	13.59	21.29
ROE (%)	16.06	19.16	19.73	18.75	20.76
ROA (%)	10.44	14.95	18.69	9.26	9.67
EBIT Margin (%)	13.78	34.40	31.41	26.58	8.74
Net Margin (%)	11.06	26.88	28.10	20.60	6.90
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

	Sanjivani Pa	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Revenue Growth (%)	-7.30	10.69	15.01	9.59	31.10
EBIT Growth (%)	-8.76	24.14	18.45	16.84	-12.99
Net Profit Growth (%)	-7.75	-9.09	19.61	62.68	-7.49
EPS Growth (%)	-11.55	14.40	17.73	67.41	-18.33
Book Value Growth (%)	--	17.30	23.77	10.19	7.70

	Sanjivani Pa	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Price / Earnings	31.17	27.54	32.39	27.47	99.95
Price / Book Value	4.61	4.82	5.72	4.48	19.18
Dividend Yield (%)	0.00	1.61	0.14	0.55	0.52
EV/EBITDA	23.56	19.26	25.92	17.70	73.50
Market Cap (₹ Cr)	--	18,318.10	15,219.80	19,292.77	21,515.93

	Sanjivani Pa	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Debt to Equity	0.14	0.00	0.00	0.24	0.00
Short term debt to equity ratio	--	0.00	0.00	0.14	--
Current Ratio	2.24	6.06	6.70	0.74	1.77
Quick Ratio	1.80	5.31	5.59	0.53	0.73
Interest Coverage	20.94	130.11	959.59	4.45	40.90

	Sanjivani Pa	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Debtors to sales (%)	16.59	7.07	36.10	21.07	8.79
Asset Turnover	0.92	0.52	0.63	0.45	1.39
Receivable days	--	29.10	110.70	54.07	35.81
Inventory Days	--	69.53	65.86	32.16	82.25
Payable days	--	76.77	105.88	140.91	124.39
Cash Conversion Cycle	--	21.86	70.68	-54.68	-6.33

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.